GSA Capital Partners LLP Has $1.14 Million Holdings in Incyte Co. (NASDAQ:INCY)

GSA Capital Partners LLP trimmed its holdings in shares of Incyte Co. (NASDAQ:INCY) by 24.8% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 20,045 shares of the biopharmaceutical company’s stock after selling 6,613 shares during the quarter. GSA Capital Partners LLP’s holdings in Incyte were worth $1,142,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Fisher Asset Management LLC raised its position in shares of Incyte by 0.4% in the fourth quarter. Fisher Asset Management LLC now owns 44,169 shares of the biopharmaceutical company’s stock valued at $2,773,000 after buying an additional 187 shares in the last quarter. 180 Wealth Advisors LLC increased its stake in Incyte by 4.5% during the 1st quarter. 180 Wealth Advisors LLC now owns 4,764 shares of the biopharmaceutical company’s stock worth $271,000 after acquiring an additional 204 shares during the period. Berger Financial Group Inc raised its holdings in Incyte by 0.4% in the 4th quarter. Berger Financial Group Inc now owns 60,468 shares of the biopharmaceutical company’s stock valued at $3,797,000 after acquiring an additional 212 shares in the last quarter. Allworth Financial LP lifted its position in shares of Incyte by 40.0% during the 4th quarter. Allworth Financial LP now owns 802 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 229 shares during the period. Finally, Grandfield & Dodd LLC grew its holdings in shares of Incyte by 1.8% during the 4th quarter. Grandfield & Dodd LLC now owns 18,390 shares of the biopharmaceutical company’s stock worth $1,155,000 after purchasing an additional 319 shares in the last quarter. Institutional investors and hedge funds own 96.97% of the company’s stock.

Insiders Place Their Bets

In other Incyte news, insider Thomas Tray sold 1,093 shares of the stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $58.91, for a total transaction of $64,388.63. Following the transaction, the insider now directly owns 21,634 shares in the company, valued at approximately $1,274,458.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, EVP Barry P. Flannelly sold 19,164 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $60.00, for a total transaction of $1,149,840.00. Following the transaction, the executive vice president now directly owns 66,377 shares of the company’s stock, valued at approximately $3,982,620. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Thomas Tray sold 1,093 shares of the stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $58.91, for a total value of $64,388.63. Following the completion of the transaction, the insider now owns 21,634 shares in the company, valued at approximately $1,274,458.94. The disclosure for this sale can be found here. 17.50% of the stock is currently owned by corporate insiders.

Incyte Trading Down 1.1 %

Shares of INCY traded down $0.65 during trading hours on Wednesday, hitting $60.05. 729,256 shares of the stock were exchanged, compared to its average volume of 2,592,584. Incyte Co. has a fifty-two week low of $50.27 and a fifty-two week high of $67.36. The business has a 50-day moving average of $58.38 and a 200-day moving average of $58.55. The firm has a market capitalization of $13.48 billion, a P/E ratio of 18.45, a price-to-earnings-growth ratio of 1.25 and a beta of 0.73. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.47 and a quick ratio of 3.43.

Incyte (NASDAQ:INCY) last posted its quarterly earnings data on Tuesday, April 30th. The biopharmaceutical company reported $0.38 earnings per share for the quarter, missing the consensus estimate of $0.69 by ($0.31). The business had revenue of $880.89 million during the quarter, compared to the consensus estimate of $935.85 million. Incyte had a return on equity of 12.83% and a net margin of 19.78%. On average, research analysts expect that Incyte Co. will post 3.57 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Truist Financial reaffirmed a “buy” rating and set a $83.00 price objective (down previously from $84.00) on shares of Incyte in a research report on Wednesday, May 1st. Oppenheimer reduced their price target on shares of Incyte from $92.00 to $84.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 24th. Bank of America decreased their price objective on shares of Incyte from $69.00 to $67.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 13th. TD Cowen cut their target price on Incyte from $88.00 to $80.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Incyte in a research note on Tuesday, June 18th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $73.44.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.